CervoMed Inc. reported positive 32-week extension results from its Phase 2b RewinD-LB study of oral neflamapimod in patients with Dementia with Lewy Bodies, the second-most common form of dementia. The drug cut the risk of clinically significant worsening on the Clinical Dementia Rating Sum of Boxes by 54% versus control, improving to 64% in participants with minimal Alzheimer’s disease co-pathology, according to data presented at the Alzheimer’s Association International Congress. Investigators also recorded an 18.4 pg/mL mean reduction in plasma glial fibrillary acidic protein—a marker of neurodegeneration—which deepened to 21.2 pg/mL in the lower-ptau181 subgroup. A newer capsule formulation that achieved target plasma levels delivered a 40% lower rate of clinical worsening compared with an older batch, while safety profiles remained comparable. Bolstered by the findings, the Boston-based company said it will meet the U.S. Food and Drug Administration in the fourth quarter to finalise a Phase 3 programme. Trading in CervoMed was briefly halted after the announcement; the stock later rose roughly 59% in pre-market dealings.